135
Participants
Start Date
July 29, 2019
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2046
Carboplatin
Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
Cisplatin
"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
Etoposide
"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
Hopital de Sion, Sion
Inselspital Bern, Bern
Kantonsspital Graubuenden, Chur
Kantonsspital Graubünden, Chur
UniversitätsSpital Zürich, Zurich
Kantonsspital Winterthur, Winterthur
Vivantes Klinikum Am Urban, Berlin
Helios Klinikum Berlin-Buch, Berlin
Universitätsklinikum Hamburg-Eppendorf, Hamburg
ASKLEPIOS Kliniken, Hamburg
Evang. Kliniken Essen-Mitte, Essen
RKH Klinikum Ludwigsburg, Ludwigsburg
Universitätsklinikum Tübingen, Tübingen
Rotkreuzklinikum München, München
Universitätsklinikum Ulm, Ulm
Universitaetsspital-Basel, Basel
Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona
Centre Hospitalier Universitaire Vaudois CHUV, Lausanne
Kantonsspital - St. Gallen, Sankt Gallen
German Testicular Cancer Study Group
OTHER
Swiss Cancer Institute
OTHER